In the CLL14 study, patients with previously untreated chronic lymphocytic leukemia (CLL)
and coexisting conditions were randomized to 12 cycles of venetoclax-obinutuzumab (Ven …

Patients with chronic lymphocytic leukemia (CLL) exhibit diverse clinical outcomes. An
expanding array of genetic tests is now employed to facilitate the identification of patients …

Simple Summary Diffuse large B-cell lymphoma is a heterogeneous entity comprised of
several distinct biological subtypes. Multiple molecular studies have attempted to classify …

Simple Summary In this study, we present a retrospective analysis of a large cohort of CLL
patients with a particular focus on those with a borderline immunoglobulin heavy variable …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially
different manifestations of the same disease that are similarly managed. A number of …

Chronic lymphocytic leukemia (CLL) treatment has undergone a significant evolution with a
shift from historical chemotherapeutic regimens to targeted therapies such as Bruton …

Introduction Bruton tyrosine kinase inhibitors (BTKi) have been used for the management of
human diseases since the approval of the first-in class agent, ibrutinib, by the Food and …

Therapeutic targeting of apoptosis with small molecule B-cell lymphoma 2 (BCL-2) inhibition
with venetoclax is highly efficacious in CLL, leading to sustained deep responses …

Frontline therapy for chronic lymphocytic leukemia (CLL) has substantially advanced in the
previous decade. While monotherapy with a Bruton's tyrosine kinase (BTK) inhibitor is an …

Introduction In the last decade, BTK inhibitors and the BCL-2 inhibitor venetoclax have
replaced immunochemotherapy in the treatment of CLL. Areas covered This review …